Molecular Advances in Preeclampsia and HELLP Syndrome

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Pathophysiology

Background:

• Preeclampsia (PE) and HELLP syndrome are major causes of maternal and perinatal mortality.
• These hypertensive diseases of pregnancy (HDP) are linked to maternal inflammation and endothelial activation.
• Elevated von Willebrand factor antigen (vWF:Ag) and complement activation (C5b-9) are observed in PE/HELLP.

Purpose of the Study:

• To review the latest molecular advances in the pathophysiology of PE/HELLP syndromes.
• To evaluate recent data on vWF:Ag, ADAMTS-13, and complement system dysregulation in PE.
• To discuss the diagnostic and therapeutic implications of these findings.

Main Methods:

• Literature review of recent medical data.
• Analysis of molecular markers including vWF:Ag, ADAMTS-13 activity, and complement system components.
• Evaluation of diagnostic and therapeutic strategies.

Main Results:

• Elevated vWF:Ag levels and normal to decreased ADAMTS-13 activity are characteristic of PE/HELLP.
• Evidence suggests significant complement activation, indicated by C5b-9, in the utero-placental unit.
• These molecular alterations are associated with disease progression and hold diagnostic significance.

Conclusions:

• Dysregulation of vWF and the complement system are key in PE/HELLP pathophysiology.
• Understanding these molecular pathways can improve diagnosis and management of HDP.
• A current diagnostic and therapeutic algorithm is proposed based on these findings.